[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

3 clusters · 8 sources · 21 days · First seen · Last updated

Brazil pharmaceutical supply and production strategy

Overview

In late July 2026, Brazil reported severe drug shortages at high‑cost medication centers, with patients experiencing long waits and missing essential treatments for conditions such as cancer and epilepsy. At the Cemac Juarez Barbosa in Goiânia, patients reported insufficient staffing and a lack of medication, forcing some to risk their employment. These shortages were linked to global supply‑chain strains and delays from the Ministry of Health and vendors.

By early August, the focus shifted to structural causes. While approximately 70% of medicines consumed in Brazil are produced locally, the sector depends heavily on imported active ingredients from China and India, facing hurdles such as high logistics costs and trade‑defence weaknesses. Concurrently, a study revealed that roughly 90% of Brazilians engage in self‑medication, with toxicologists warning that improper use of over‑the‑counter drugs increases risks of kidney injury and gastrointestinal bleeding.

In response to these vulnerabilities and the significant trade deficit in health products, the Brazilian government announced a strategic goal in mid-August to increase domestic production of medicines and active pharmaceutical ingredients to 70% of the Unified Health System (SUS) needs by 2033. To achieve this, Vice President Geraldo Alckmin highlighted tax reforms providing exemptions for certain inputs and the authorization of the BNDES to support companies accessing international markets under the ‘Plano Brasil Soberano’.

Entities

Brazil · BNDES · Sistema Único de Saúde · Walker Lahmann · Centro Estadual de Medicação de Alto Custo (Cemac) Juarez Barbosa

Timeline

  1. 8 days ago

    [BUSINESS] 2 sources
    Brazil targets 70% domestic pharmaceutical production by 2033

    Brazil aims to produce 70% of the medicines and pharmaceutical ingredients required by the SUS domestically by 2033 to reduce trade deficits and increase national sovereignty.

  2. 24 days ago

    [HEALTH] 4 sources
    Brazil's pharmaceutical sector faces production bottlenecks and widespread self‑medication

    Brazil produces most of its medicines but depends on imported ingredients, while 90% of citizens self‑medicate, raising safety concerns.

  3. 28 days ago

    [HEALTH] 2 sources
    Brazil confronts growing drug shortages in pharmacies and hospitals

    Global drug‑supply strains and limited manufacturers are causing shortages, while Brazil’s Cemac center in Goiânia faces long waits and missing high‑cost medicines for serious illnesses.

Sources

abradilan.com.br · brasilemfolhas.com.br · conteudos.cnnbrasil.com.br · diariodopara.dol.com.br · exame.com · historicalaccounts.com · ohoje.com · revistadafarmacia.com.br

This summary has been updated 1 time: see revision history